FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients - Bristol-Myers Squibb (NYSE:BMY)

FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients - Bristol-Myers Squibb (NYSE:BMY)

The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). The approval comes ahead of over two months of the June 23, 2025, Prescription Drug User F…

BMS bags a double-quick colorectal cancer approval from FDA

The FDA has approved Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for patients with a particular form of colorectal cancer

Ferring gene therapy sales grow; ASH calls for restoration of cut CDC division

In its first full year on the U.S. market, bladder cancer treatment Adstiladrin earned about $77 million. Elsewhere, Lilly backed a cancer drug startup and Bristol Myers won a new Opdivo approval.

FDA Approves Updated Label for Tryvio (aprocitentan)

Updated label for Tryvio (aprocitentan) removes the REMS requirement.

FDA approves nivolumab with ipilimumab for MSI-H, dMMR colorectal cancer

The federal agency greenlit nivolumab with ipilimumab for treating MSI-H/dMMR colorectal cancer in adults and children 12 years and up.

FDA Approves Nivolumab + Ipilimumab for Certain Patients With CRC

The CRC indication is the latest approval for the combination therapy, which demonstrated improved PFS vs chemotherapy and nivolumab monotherapy.